(Press-News.org) February 10, 2026 – Insilico Medicine (“Insilico”, 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited (“CMS”, 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.
According to the collaboration agreement, the two parties will combine Insilico Medicine’s validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS’s experienced R&D team and deep disease-area expertise to jointly advance the co-development of no fewer than two R&D programs. Insilico Medicine is also expected to receive R&D funding support of up to several tens of millions of HKD for each program. This collaboration will fully leverage the complementary strengths of both parties across the entire value chain of drug discovery, clinical development, and commercialization. By integrating resources and technologies, the companies aim to accelerate the research, development, and translation of high-potential innovative therapies. Insilico will capitalize on its Pharma.AI platform and its technological capabilities in target discovery, small-molecule design, and optimization to enable efficient screening and validation of candidate molecules. CMS will contribute its extensive experience and well-established networks in clinical development strategy, regulatory pathway planning, clinical trial execution, and commercial promotion, to advance projects from preclinical stages into clinical development and ultimately to commercialization.
Under this collaboration framework, the parties will jointly optimize project decision-making, shorten development timelines, and improve clinical success rates, thereby significantly accelerating the entire journey from laboratory discovery to patient access. This strong partnership is expected not only to bring innovative medicines into clinical development and to market more rapidly, but also to offer patients more innovative and accessible treatment options, ultimately improving health outcomes and quality of life.
Mr. LAM Kong, the Chairman, Chief Executive Officer, President and Executive Director of CMS said: “CMS has always been committed to addressing clinical needs through a dual-drive model of ‘collaborative development and independent R&D.’ We continue to enrich our pipeline with global first-in-class (FIC) and best-in-class (BIC) innovative assets, efficiently advancing their clinical research, development, and commercialization to empower the continuous translation of scientific achievements into clinical practice. Insilico Medicine’s leadership in AI drug discovery platforms and data-driven R&D is strategically complementary to CMS’s capabilities in innovative R&D and clinical translation. In addition, CMS has built solid strengths in clinical development systems, regulatory submission expertise, and a broad commercialization network. We look forward to further deepening our collaboration on the existing foundation to accelerate the delivery of more clinically meaningful innovations to patients with greater speed and quality, improving the accessibility and affordability of medicines and better meeting the growing clinical needs.”
“We are delighted to collaborate with China Medical System,” said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. “This strategic collaboration with CMS is a key step for Insilico Medicine in advancing our mission of ‘AI‑empowered, full‑lifecycle innovative drug R&D’. Under this collaboration framework, we look forward to leveraging resource sharing and joint decision‑making to significantly shorten the development cycle of high‑potential innovative drugs, enhance translational efficiency and clinical success rates, and accelerate the journey of more innovative molecules from ‘proof of concept’ to truly ‘benefiting patients’. Going forward, the two parties will continue to deepen multi‑dimensional collaboration in pipeline layout, clinical strategy, and global partnerships, further improving the accessibility of innovative medicines, providing patients with more differentiated treatment options.”
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About CMS
CMS (HKEX stock code:867; SGX stock code: 8A8) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses, bringing economies of scale in specialty fields.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
Forward-Looking Statements:
This press release contains forward-looking statements relating to the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial performance. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends”, “visions”, “schedule” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company at the time of this press release in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations.
All of the forward-looking statements made in this press release are qualified by these statements. Consequently, the inclusion of forward-looking statements in this press release should not be regarded as representations by the Board or the Company that the plans and objectives will be achieved, and investors should not place undue reliance on such statements.
The Company, its Board, the employees and the agents of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this press release; and (b) no liability for any losses in the event that any of the forward-looking statements do not materialise or turn out to be incorrect.
END
AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases
2026-02-10
ELSE PRESS RELEASES FROM THIS DATE:
AI-generated arguments are persuasive, even when labeled
2026-02-10
Labeling content as AI-generated does not make it less persuasive than human-authored or unlabeled content, according to a study. Isabel O. Gallegos and colleagues conducted a survey experiment with 1,601 Americans to test whether authorship labels affect the persuasiveness of AI-generated messages about public policies. Participants viewed an AI-generated message about one of four policy issues, including geoengineering, drug importation, college athlete salaries, and social media platform liability. Participants were randomly assigned to see the message labeled as created by an expert ...
New study reveals floods are the biggest drivers of plastic pollution in rivers
2026-02-10
Plastic pollution has become a major global environmental concern as modern societies rely increasingly on plastic products. Much of this plastic waste eventually reaches the ocean, with rivers acting as the main transport routes from urban, agricultural, and other landscapes, thereby affecting the lives of marine organisms. Over time, larger plastic items break down into smaller pieces known as microplastics (less than 5 millimeters) and mesoplastics (between 5 and 25 millimeters). These particles can spread ...
Novel framework for real-time bedside heart rate variability analysis
2026-02-10
Real-time and early detection of minute changes in the functioning of the cardiovascular system is crucial for managing critically ill patients, such as newborns and older adults, and can significantly affect their outcomes. Heart rate variability (HRV) is the minute, yet normal, fluctuations between consecutive heartbeats, usually measured through the electrocardiogram (ECG). HRV is a well-established, quantitative, and noninvasive measure for assessing autonomic nervous system activity.
However, despite its high value for patient monitoring ...
Dogs and cats help spread an invasive flatworm species
2026-02-10
A study published in the journal PeerJ, conducted by a researcher from the Institute of Systematics, Evolution and Biodiversity (ISYEB) at the French National Museum of Natural History, in collaboration with a researcher from James Cook University in Australia, reveals that domestic animals are involved in the transport of an invasive flatworm species in France.
Terrestrial flatworms (Platyhelminthes) are invasive species that primarily spread through the transport of plants, largely driven by human activities. However, one question remained unanswered: how do these very slow-moving animals manage to colonize ...
Long COVID linked to Alzheimer’s disease mechanisms
2026-02-10
The increased size of, and lesser blood supply to, a key brain structure in patients with Long COVID tracks with known blood markers of Alzheimer’s disease and greater levels of dementia, a new study finds.
Led by NYU Langone Health researchers, the study concerns the choroid plexus (CP), a network of blood vessels lined by cells that produce cerebrospinal fluid, which cushions the brain and forms a protective barrier between the fluid and the bloodstream. The CP regulates immune system responses (inflammation) and waste clearance in the brain. Past studies show that the COVID-19 virus can damage the cells lining ...
Study reveals how chills develop and support the body's defense against infection
2026-02-10
When running a fever during infection, we often feel chills, which prompt us to take action to warm ourselves, such as turning on a heater or adding layers of clothing. Increased body temperature helps inhibit pathogen growth and boosts immune cell activity.
A recent rat study by a Nagoya University team identified the neural mechanism underlying chills, a cold sensation that supports the body's response to infection. The findings were published in The Journal of Physiology.
When mammals are infected, their immune system produces a pyrogenic ...
Half of the world’s coral reefs suffered major bleaching during the 2014–2017 global heatwave
2026-02-10
Benefits to society from coral reefs, including fisheries, tourism, coastal protection, pharmaceutical discovery and more, are estimated at about $9.8 trillion per year. For the first time, an international team led by Smithsonian researchers estimated the extent of coral bleaching worldwide during a global marine heatwave, finding that half of the world’s reefs experienced significant damage. Another heatwave began in 2023 and is ongoing. The analysis was published today in Nature Communications.
It takes two partners to make a coral: a tiny animal related to a jellyfish that secretes the hard ...
AI stethoscope can help spot ‘silent epidemic’ of heart valve disease earlier than GPs, study suggests
2026-02-10
Artificial intelligence could help doctors detect serious heart valve disease years earlier, potentially saving thousands of lives, a new study suggests.
Researchers led by the University of Cambridge analysed heart sounds from nearly 1,800 patients using an AI algorithm trained to recognise valve disease, a condition that often goes undiagnosed until it becomes life-threatening.
The AI correctly identified 98% of patients with severe aortic stenosis, the most common form of valve disease requiring surgery, and 94% of those with severe mitral regurgitation, where the heart valve doesn’t fully close and blood leaks backward across the valve.
The technology, which works with ...
Researchers rebuild microscopic circadian clock that can control genes
2026-02-10
Our circadian clocks play a crucial role in our health and well-being, keeping our 24-hour biological cycles in sync with light and dark exposure. Disruptions in the rhythms of these clocks, as with jet lag and daylight saving time, can throw our daily functioning out of sync.
University of California San Diego scientists are now getting closer to understanding how these clocks operate at their core.
In the journal Nature Structural and Molecular Biology, researchers based in UC San Diego’s Department of Molecular Biology (School of Biological Sciences) and Center for Circadian Biology, along with national ...
Controlled “oxidative spark”: a surprising ally in brain repair
2026-02-10
Oxidative stress is a direct consequence of an excess in the body of so-called “free radicals” – reactive, unstable molecules that contain oxygen. Free radicals are normal metabolic by-products and also help to relay signals in the body. In turn, oxidative stress (an overload of these molecules) can be caused by lifestyle, environmental and biological factors such as smoking, high alcohol consumption, poor diet, stress, pollution, radiation, industrial chemicals, and chronic inflammation. When this occurs, it creates an imbalance ...